Efficacy and safety of Infliximab in systemic sarcoidosis according to GenPhenReSa organ-involvement phenotype: a retrospective study of 55 patients

Infliximab is currently recommended as a third-line treatment for refractory sarcoidosis. Data in function of clinical phenotype are currently lacking. We evaluated patients ’ characteristics and responses to i...

Source: Respiratory Research - March 14, 2024 Category: Respiratory Medicine Authors: Etienne Rivi ère, Wendy Jourde, Noémie Gensous, Xavier Demant, Emmanuel Ribeiro, Pierre Duffau, Patrick Mercié, Jean-François Viallard and Estibaliz Lazaro Tags: Research Source Type: research